• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • Biomarker Data Analyses
    • Biomarker Regulatory Services
  • Products
    • EASYCOV
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • R&D
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media

  • PROTEOMICS Soluble Markers

    Immunoassays to measure circulating and soluble markers

  • GENOMICS TRANSCRIP- TOMICS

    Complete genome and transcriptome analysis with Next-Generation Sequencing and qRT-PCR Profiling

  • FLOW CYTOMETRY

    Preclinical services from target selection and validation up to clinical development for diagnosis, prognosis and monitoring of disease.

  • ASSAY DEVELOPMENT

    Customized assays for specific requirements to implement correct biomarker endpoints

  • MONOCLONAL ANTIBODIES

    Comprehensive services from antigen definition to production and purification of antibodies.

  • BIOBANKING

    A regulatory compliant biobank in the heart of Europe, operated by comptent staff, under strict quality management

  • BIOMARKER DATA ANALYSES

    From exploratory analyses up to predictive models, we offer innovative data analysis services to identify novel biomarkers

  • Biomarker Regulatory Services

    Regulatory qualification of biomarker-based panels in EU and US

    • Firalis BIOMARKER SERVICES

     

    Firalis provides a comprehensive range of biomarker services from research to clinical trials in key therapeutic areas. Flexible stratification at scientific and technical levels supports biomarker discovery, validation, evaluation and qualification activities. Using our strong expertise and a cutting-edge laboratory equipment, we develop and deliver solutions for biomarker assays customized to your projects.

     

    Our partnerships with the pharma industry have resulted in a high sense of quality and reliability in the data we deliver. Clients are invited to choose from our assay menu and use validation data available ad hoc or from a customized procedure.

     

    Firalis is certified ISO:13485 (GMP compliant) and ISO:9001 for the development & production of CE-marked assays, certified NF S 96-900 for its biobank and accredited* ISO 17025 (GCLP compliant) for testing laboratory.

     

    * Click here to view the methods accredited under accreditation number 8-3139. For full scope visit www.cofrac.fr

    1907283661086-firalis-bioanalytical-platforms.png

    Contact us today at sales{at}firalis.com and get additional information on our technical platforms and capabilities

    Read our General Terms and Conditions of Sales for Services  (in French: Conditions Générales de Vente et de Prestations de Services)

    • Yvan DEVAUX, PhD, Head of Cardiovascular Research Unit at LIH

      "The ability of Firalis in reaching large international research grants and collaborating with the best academia, with the reflexes and abilities of a private company, is of great value for successful public-private partnerships. Being from the publicly-funded Luxembourg Institute of Health (LIH), it is a great achievement to work with industrials, and working with Firalis is a rich training and rewarding experience, with collaborative research projects leading to scientific publications and ultimately to valuable research and biomedical tools to push personalized medicine a step forward."
    • Olivier DANOS, PhD, Sr. VP & CSO at REGENXBIO Inc.

      "Initiating and coordinating several collaborative research projects, acquisition of many of the most challenging research funds, from both sides of the Atlantic, all contributed to the acceleration of Firalis, to become one of the European leaders in the field of biomarker discovery and validation in less than 10 years. I am proud to be a founding associate and a member of the scientific advisory board."

    Follow us on

    Contact Firalis

    Firalis Group

    © Copyright 2020 all rights reserved. 

    The company logos, products and service marks are trademarks or registered trademarks of Firalis.

    -----------------------------------------------------------------------------------------------------------------------

    Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

    -----------------------------------------------------------------------------------------------------------------------

    Headquarter : 17 Rue du Fort 68330 Huningue FRANCE

    follow Firalis on
    Linkedin

    EasyCOV

    The first Covid-19 Rapid Salivary Test

    99% Specific & 86% Sensitive

     

    • No more painful NP Swabs
    • No need for a Laboratory
    • Since 22/01/2021 officially equal to an RT-PCR Test!
    • Sample to Result time only 40 Minutes!
    • Result in an instant thanks to RT-LAMP Technology

     

    LEARN MORE &

    GET YOUR QUOTATION NOW !

    EasyCOV

    The first Covid-19 Rapid Salivary Test

    99% Specific & 86% Sensitive

     

    • No more painful NP Swabs
    • No need for a Laboratory
    • Since 22/01/2021 officially equal to an RT-PCR Test!
    • Sample to Result time only 40 Minutes!
    • Result in an instant thanks to RT-LAMP Technology

     

    LEARN MORE &

    GET YOUR QUOTATION NOW !